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ABSTRACT 
Hydroxychloroquine (HCQ) is classified under the class of drugs called antimalarials. This is used for preventions and treatment of malaria. HCQ is 
also used in the treatment of DLE (Discoid Lupus Erythematosus) or SLE (Systemic Lupus Erythematosus) and RA (Rheumatoid Arthritis). Recently, 
this drug attracts its attention by scientists of all of the worlds for its potential activity in the improvement of conditions of covid patients. There are 
many clinical trials are under process to prove its activity against this dangerous virus. The presented review describes different analytical 
procedures for the analysis of HCQ in various components available in the currently available literature. The paper will be certainly helpful for the 
scientists and researchers engaged in research, especially in the development of formulation or quality assurance of HCQ. The results of any clinical 
trial also includes the determination of drug in body fluids for interpretation of data. The analytical methods described here are explained in three 
parts; spectrophotometry, chromatography and other (including capillary electrophoresis and electroanalytical methods) 
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INTRODUCTION 
Hydroxychloroquine (HCQ) is more commonly used than 
chloroquine, is a well-tolerated Disease-modifying anti-rheumatic 
drugs (DMARD) that is commonly used in combination therapy 
regimens for RA [1]. The IUPAC name of HCQ (C18H26ClN3O) is (RS)-
2-[4-(7-Chloro-4-quinolylamino)pentyl(ethyl)amino]-ethanol [2]. 
The HCQ is synthesized by an antimalarial drug, chloroquine (CQ) with 
incorporating hydroxyl group in its structure, in the year 1946. After the 
discovery of HCQ, it was found to be two to three times less toxic than CQ [3]. 
Hydroxychloroquine (fig. 1) is a 4-aminoquinoline shown to possess 
the above-described activities. This is also known to be an 
immunosuppressant drug. The abnormalities caused by HCQ 
therapy is rare compared with CQ, which is also associated with 
acute liver lesion [4]. HCQ is available in the market in the form of 
tablet formulations. The dose of HCQ ranges from 100 mg to 1.2 
grams per day, quickly absorbed in two to four hours. The absorbed 
portion is about 74%±13%. The blood concentration of HCQ rises 
shortly after absorption but fall rapidly due to fast distribution into 
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Hydroxychloroquine Desethylchloroquine Bisdesethylchloroquine Monodesethylhydroxychloroquine 
Fig. 1: Chemical structures of HCQ and three major metabolites 
 
Antimalarial drugs modulate the immune system through their 
known ability to influence the pH in intracytoplasmic vesicles. As 
discussed in the previous section, after fast absorption, the deposits 
of HCQ and CQ extensively distributes in the tissues. The drug is 
concentrated intracellularly, particularly in acidic cytoplasmic 
vesicles. The deposition of HCQ in immune system cells is the reason 
of its antirheumatic effect [6]. 
The novel virus spread (Covid-19) from Wuhan province of China in 
the year 2019 is now a threat for economy and health infrastructure 
[7]. The world’s apex health organization, WHO declared this as 
pandemic because of rapid spread in almost every part of the world 
[8, 9]. In the stage of writing this article, the available literature 
indicates more than 300 clinical trails (ongoing), and different drugs 
are in the phase of evaluation for potential effects against covid-19 
[10].  
One of the advantages of HCQ over its parent drug CQ is tolerance in 
higher doses form longer periods. The US FDA approved HCQ for its 
marketing in their country in 1994 [11]. The effect of HCQ and CQ on 
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viral replication goes beyond the inhibition of cytokines. These 
drugs are weak bases known to influence acidic vesicles and 
inhibition of many enzymes. The enzyme glycosyl-transferases is 
inhibited by HCQ and decreasing the occurrence of viral replication 
of some of its families. This is believed to be one of the potential 
explanations of its antiretroviral mechanism of these drugs [12].  
HCQ and covid-19 
The fast outbreak of new coronavirus (SARS-CoV-2) has now 
become a serious concern for health for almost all countries of the 
world [13, 14]. The mechanism of entry of this virus into the host 
cell is believed to be the result of interaction between ACE2 
(Angiotensin-converting enzyme) and spiral protein of virus [15]. 
This is now established that elderly people and people with other 
comorbidities e. g. diabetes (TYPE 2) are in high risk with a high 
death rate [16]. 
In spite of best efforts by almost all health-related researchers, till 
the mid of June of this year, we have not found any therapeutic 
option for this virus and this is the reason of declared “public health 
emergency” in most of the countries, including Indian subcontinent. 
Researchers are investigating many drugs for treatment, including 
these low-cost antimalarials; HCQ and CQ [17]. 
The reputed government research organization of India, Indian 
Council of Medical Research (ICMR) recommended the dose of HCQ 
400 mg twice on day 1 and once/week after that) for 
chemoprophylaxis to health care workers handling patients of covid in 
both confirmed and suspected infections cases. Also recommended for 
household contacts (asymptomatic) for any confirmed cases [18] 
The healthcare system of the whole world is facing an alarming 
situation because of spread of new coronavirus. Thus, there is an 
urgent requirement for therapeutic option for control of new 
coronavirus. HCQ is a derivative of Chloroquine (CQ), currently 
under investigation may be therapeutic option against COVID-19 
infection. HCQ was found to have less acute poisoning than CQ and 
share a similar mechanism of action and structure [19]. 
The mechanism of action of HCQ against covid 19 virus is still under 
investigation. It is believed to change the pH of endosomes. Because 
of this the entry of virus, its transportation and postentry events are 
believed to be prevented [17]. The report suggests halting 
replication and modification of virus and also inhibition of glycosyl-
transferases [20]. In vivo, hydroxychloroquine is metabolized into 
chloroquine [21]. 
The HCQ and its parent drug CQ both have comparable 
pharmacological activity as antimalarial agents, but former if 
preferred due to less ocular toxicity. The available literature 
suggested the prolongation of QT interval by using CQ in 
combination with other antiretroviral drugs such as ritonavir or 
lopinavir, but this problem is less in HCQ and this is the reason of its 
selection for covid patients [22] 
Thus, apart from the development of medication in this pandemic, 
there is a definite need of the literature presented here to help 
scientists or researchers involved in the investigation of 
development of a formulation of HCQ. This article is a 
comprehensive review of analytical methods published so far for the 
analysis of HCQ in a different mixture of components. 
MATERIALS AND METHODS 
Author searched various online libraries available online related to 
determination of Hydroxychloroquine. The databases searched are, 
pubmed, wiley, sciencedirect, taylor and francis, nature, BMJ and 
google scholar. The keywords used for search are ‘determination of 
Hydroxychloroquine’, ‘estimation of Hydroxychloroquine’, and 
‘Hydroxychloroquine in covid-19.  
Analytical methods 
Spectrophotometry methods 
The quantitative analysis performed by spectrophotometry is due to 
the interaction of radiations of ultraviolet and some part of infrared 
region with sample and has an influence on variety of different fields 
of science and technology. There are many changes in a 
spectrophotometer in last few decades due to advancement in 
technology with inclusion of many new features for different type of 
samples and optical properties [23].  
Five spectrophotometric methods [24-27] were found from various 
sources available in internet. Feraz et al. [24] used USP method [26] 
and performed quality by design in the determination of 
hydroxychloroquine in tablet formulations. The limit of quantitation 
and limit of quantitation found are 1.27 and 0.38 µg/ml respectively.  
In another method 0.1 N HCl was used as diluent and determination 
performed at same wavelength as in the previously described 
method. Pharmacopeial method found cited here is referred from 
United States Pharmacopoeia [25]. 
Two methods in single paper in which one involves simple 
spectrophotometry method and another first derivative method 
developed by Mehta and Patel. In this method water is used as 
diluent for the preparation of sample in contrast to other methods 
using acidic medium [27]. 
 
Table 1: Summary of UV spectrophotometry method 
Calibration curve/Target 
concentration 
Solvent/Diluent Wavelength LOD and LOQ Matrix Reference 
8-12 µg/ml 0.01 M HCl 342 nm 0.38 and 1.27 µg/ml Raw and formulation [24] 
1-20 µg/ml 0.1 N HCl 343 nm Not mentioned Raw and formulation [25] 
10 µg/ml Dil. HCl (1 in 100) 343 nm - Raw material [26] 
2-12 μg/ml Water 251-261 nm 0.37, 1.1212 µg/ml Bulk drug and 
formulation 
[27] 
347.80 nm (First 
derivative) 
0.3145, 0.9530 µg/ml 
 
Chromatography methods 
There are three different characteristics of chromatography 
separations: (a) these are a physical method for separation of 
components; (b) involvement of two different phases, stationary 
phase and mobile phase; and (c) separation of components on the 
basis of distribution constants of individual components in 
stationary and mobile phase. There are several important factors 
responsible for the acceptable separation of sample [28].  
The first paper related to the chromatography method was found 
to be published in 1985. HCQ and its metabolites are basic 
compounds and fluoresce at high pH, facilitating sensitive 
detection using chromatographic methods. This may be the 
reason that most of the methods utilizing spectrometry detection 
are based on fluorescence technique. First published paper is 
assay for HCQ and three major metabolites (fig. 1), using 
fluorescence detection in blood and plasma of RA patients. In 
this method chloroquine was used as an internal standard. Nine 
different anti-inflammatory drugs indicated in rheumatoid 
arthritis administered together with HCQ were found not 
interfere with the method [29].  
The next method is related to quantitation for HCQ and three major 
metabolites (fig. 1), in human plasma using a fluorescence detection 
method. Determinations were performed in two sets of samples (1) 
fresh and immediately prepared sample, (2) stored for 18 d in 
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freezer prior for analysis. This method is useful for application in 
clinical samples, as claimed by researchers [30]. 
Determination of HCQ and its three metabolites in blood and urine 
samples is also available with the claimed to be without the 
interference of chloroquine or quinine in the sample. Analyses was 
performed in whole blood and urine samples from two healthy, 
male, adult volunteers during weekly antimalarial 
chemoprophylaxis. Fluorescence detector was used at λex = 320 nm 
and λem = 380 nm [31]. 
Wainer and Iredale (1992) developed method for the determination of 
the enantiomers of hydroxychloroquine, and three major metabolites 
(fig. 1), in plasma, using a Chiral-AGP chiral stationary phase. Method 
validated for the pharmacokinetic of HCQ in rabbit and includes two 
steps (1) achiral chromatography and (2) enantioselective 
chromatography using two different mobile phases [32]. 
Another method is achiral-chiral HPLC system has been developed 
for the quantitative analysis of HCQ in urine. Determinations 
performed for HCQ and the same three metabolites discussed 
earlier. This study complies the analysis in single oral dose 
pharmacokinetic study (200 mg HCQ sulfate) [33].  
Analysis and separation method of HCQ enantiomers and 
metabolites in two steps, developed by Wei et al. [34]. In this method 
authors found unsatisfactory separation using chiral column for HCQ 
enantiomers and thus developed method in two stages. In the first 
step achiral separation is performed and racemates were collected. 
The second step is the separation of enantiomers using chiral 
column for drugs and metabolites [34]. 
Another HPLC method for analysis of quinine, HCQ, CQ and DCQ is 
also available. The method is applied in whole blood, serum, and 
blood (dried) adsorbed in filter paper. The method is useful for 
analysis in a particularly small volume. Method described 
fluorescence detection and claimed to obtained within an hour of 
receipt of the sample [35]. 
Another HPLC method in serum samples for simultaneous 
determination of HCQ, CQ and corticosteroids from rheumatoid 
arthritis patients developed by Volin [36]. Patients received HCQ 
sulphate or CQ diphosphate and then determination performed in 
serum samples using diode array detection [36].  
Method to quantify enantiomers is described and applied in 
determination of HCQ in rat liver microsomes. This is a single-step 
method for chiral separation using UV detection (λ = 343 nm) [37].  
The LC–MS/MS determination is performed by using 
hydroxychloroquine-d4 as the internal standard. A high throughput 
analysis is claimed, as run time is just three minutes and applied in 
human plasma [38]. 
The LC-MS/MS analysis is performed for the separation of three 
metabolites and parent drug (HCQ) in human plasma. Method may 
be applied for monitoring blood concentration of drug and 
metabolites, especially in the case of poisoning [39]. 
Plasma determination of HCQ was developed and validated by 
using the RP-HPLC-UV method using chloroquine as an internal 
standard [40].  
Fluorescence detection clubbed with HPLC method is also available 
and applied used to monitor the blood level of HCQ in Systemic 
Lupus Erythematosus (SLE) patients [41].  
An UPLC method using UV detection is developed, aimed for analysis 
of HCQ in serum samples. Method is applied for monitoring drug 
concentration in patients suffering from Whipple’s disease and Q 
fever [42]. 
A VAMS method (volumetric absorptive microsampling) based LC–
MS/MS method is also reported for therapeutic drug monitoring. 
The absorption of a fixed volume of blood (10 µl) is possible by using 
VAMS method, with decreased variations in sampling especially 
problems related to dried blood spot are its additional advantages 
[43]. 
An HPLC-FL ion-pairing method for the determination of HCQ 
with its three metabolites i.e. DHCQ, DCQ, and BDCQ is also 
available. The method was applied for monitoring drug 
concentration in in patients suffering from Systemic Lupus 
Erythematosus (SLE). The method was also compared with the 
already available LC/MS/MS method and claimed to be applied 
for routine clinical monitoring [44]. 
The quantitation of HCQ and its three metabolites (DHCQ, DCQ, and 
BDCQ) in blood and tissues through LC-MS/MS is one of the recent 
publication. Method can also be utilized for pharmacokinetic 
monitoring of HCQ [45]. 
A recent published HPTLC with UV detection method is for the 
simultaneous determination of three different drugs in blood 
and urine samples of RA patients. The principles of Quality by 
Design were also used. Therapeutic monitoring and 
pharmacokinetic determination of drug are applications of this 
method [46]. 
Electroanalytical methods 
The recent development of electrical methods for analytical 
determinations makes them more selective, sensitive, rapid and easy 
compared to the equipment available after its development and now 
applicable for most of the fields of pharmaceutical and chemical 
analysis. Electrochemical methods nowadays enables usage for trace 
analysis also for pharmaceuticals with a sufficient degree of 
precision, accuracy, selectivity, sensitivity and reproducibility [47]. 
A differential pulse voltammetry method using glassy carbon 
electrodes developed by Arguelho et al. [48]. This is the first 
electrochemical method found in the available literature. Best 
current for analysis of HCQ was obtained at pH 4 and scan rate 
between 2 and 8 mV/s. In the width higher than 100 mV researchers 
observed loss of resolution. The detection limit reported is 
11.29±2.6 mg ml-1 [48]. 
The first capillary electrophoresis method for simultaneous analysis 
of hydroxychloroquine (HCQ) with its three metabolites, in 
microsomal fraction of liver homogenates. The quantitation limit 
reported is 125 ng/ml, and detection performed at 220 nm. The 
researchers found that major metabolite of HCQ by microsomal 
enzymes is (-)-(R)-desethylhydroxychloroquine (DHCQ) [49]. 
Another capillary electrophoresis method for determination of HCQ, 
its enantiomers and metabolites in the concentration range of 10–
1000 ng/ml for parent drug applied in human urine. The limit of 
detection and quantitation values reported were 10 and 21 ng/ml 
respectively [50].  
In other electrochemical method determination was performed 
by using glassy carbon electrode prepared in laboratory by using 
cyclic voltametry, double potential step chronocoulometry and 
linear sweep voltammetry (LSV) techniques. The detection limit 
reported in this method is 4.65 nM. The prepared modified 
electrode was then utilized for determining of HQ in human body 
fluids [51]. 
Determination of HCQ in synthetic urine and in pharmaceutical 
tablets by the square-wave voltammetry method is also available. 
The reported detection limit is 0.06 µmol L-1. The electrode utilized 
was cathodically pretreated (CPT) boron-doped diamond (BDD) 
electrode [52]. 
Potentiometric determination of HCQ in pure form, tablets and 
human urine samples using standard addition method. Silver-silver 
chloride and modified paste electrodes were used for analysis. The 
limit of detection reported was up to 5.0× 10−6 mol L-1[53]. Similar 
method by using coated graphite electrode (CGE) is also reported. 
The detection limit found is 1.8×10−5 mol L-1 and response time ≤ 
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Table 2: Summary of chromatography methods 




Methanol (80): Water(20) 
 
11 1 ml/min - - Blood and 
plasma 
[29] 
HPLC-UV CN 0.06 M Dibutylamine Phosphate 
(40): 0.05 M Monobasic sodium 
Phosphate (60)  
3.5 1.2 ml/min - - Plasma [30] 
HPLC-F ODS Hexane: tert butyl ether: 0.5% n-
butylamine in methanol (1:1:1) 
- 1 ml/min 10 ppb - Blood and 
urine  
[31] 
HPLC-UV CN 0.03 M sodium phosphate buffer, 
pH 7.0-ethanol-acetonitrile 
(79:20: 1) 
- 0.9 ml/min 10 
ng/ml 
- Plasma [32] 
HPLC-UV CN Na3PO4 Buffer (0.03 mol/l); 
ethanol; and acetonitrile (79:20: I 
- 0.7 ml/min - - Plasma and in 
urine 
[33] 








- - Plasma [34] 




2 ml/min ˂1 ng - Blood [35] 
HPLC-F Silica Methanol: water (98.5:1.5)+ 
4.705 g NH4ClO4 
8.0 1.5 ml/min - 0.005-0.01 
mg/l 
Serum, whole 







ODS 58 mmol 
monobasic NaH2PO4 buffer (7 
g/l),+6 mmol heptanesulfonic 
acid (sodium salt) (1.3 g/l) 
3.1 1.0 ml/min 2 
ng/ml 
- Serum [37] 
HPLC-UV C8 Hexane: Isopropanol (92:8)+0.1 
% Diethyl amine 







C8 Formic acid(0.1%): ACN(94:6, 
v/v) 
- 0.5 ml/min 2 
ng/ml 
- Blood [39] 
LC-
MS/MS 
ODS Water and methanol 
(Gradient)+0.1% formic acid 
- 0.5 ml/min - 25 ng/ml Blood [40] 
HPLC-UV ODS Water: Solvent (ACN: methanol: 




2.0 ml/min 0.24 
μg/ml 
0.84 μg/ml Plasma [41] 
HPLC-F ODS Glycine buffer/NaCl (pH 9.7, 100 
mmol) and methanol (46:54; v/v) 
- 1.2 ml/min 25 
ng/ml 
- Blood [42] 
UHPLC-
UV 
C18 1% triethylamine and 1 mmol 
oxalic acid 
2.4 0.5 ml/min - 0.25μg/ml Serum [43] 
LC-
MS/MS 
C8 0.1% HCOOH and 0.01% 
triethylamine in water (or 
acetonitrile) 
 0.5 ml/min 5 
ng/ml 
10 ng/ml Blood [44] 
HPLC-FL ODS Water: methanol: ACN (47:10:43 9.4 1.0 ml/min - 20 ng/ml Blood [45] 
LC–ESI–
MS/MS 
C18 Gradient: Part A: 0.2% formic 
acid in water, Part B: 0.1% formic 
acid in methanol 
- 2.0 L/min 1 
ng/ml 
- Blood and 
tissues. 
[46] 
HPTLC - Ethyl acetate: methanol: 25% 
ammonia, (8: 2: 3) 










The CQ and its hydroxyl derivative HCQ are weak bases with five 
decades usage as antimalarial agents [55]. HCQ is one of the drugs 
generated significant interest for the treatment of COVID-19 
infection. There are research published providing some idea about 
the activity of HCQ against this novel coronavirus [56]. 
HCQ, a member of the group of 4-aminoquinolines [57] and is a 
slow-acting antirheumatic drug [58]. It is administered as a racemic 
mixture [rac-HCQ] of two isomers, R(-)-HCQ and S(+)-HCQ. The 
hepatic metabolism generates three metabolites, DHCQ, BDCQ and 
DCQ. These three molecules are also chiral molecules [59]. 
There are five spectrophotometry methods found in the available 
literature. These all methods are for routine quality control of HCQ 
in bulk or formulations. Spectrophotometry methods are cheaper 
than chromatography. There are limited methods available for the 
determination of HCQ with nearly the same procedures and 
dilutions. The summary is provided under table 1. 
The HPLC methods are versatile and can be used as both analytical and 
preparative technique. Organic molecules are detected after exit from 
column using absorption pattern in UV/Visible radiation. As described 
in spectrophotometry method, HCQ showing maximum absorption at 
342 nm in UV region, many chromatography coupled with 
spectrophotometry detection method were developed [60]. The 
testing of enantiomers are quite often with HPLC in last few decade. 
The chiral stationary phase enables separation based on interaction 
between stationary phase (chiral) and isomers [61]. LC-MS methods 
nowadays emerged as powerful tool in analytical chemistry for 
complex samples for both quantitative and qualitative analysis. These 
methods possessing high separation power, high sensitivity and 
facilitates research with detailed information of analyte’s identity [62]. 
Different types of chromatography methods are available in the 
literature for the determination of HCQ in different matrices. The 
summary of chromatography methods are described under table 2. 
The research-based on photochemical degradation of HCQ, followed 
by HPLC is also available. Degradation performed by an immersion 
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lamp with emission wavelengths of 240-600 nm, 120 W. 
Degradation products were isolated first by using preparative TLC 





























Fig. 2: Photodegradation of HCQ in water and isopropyl alcohol [63] 
 
There is another paper described forced degradation studies of HCQ. 
The stress conditions applied for degradation of drug through 
hydrolysis, dry heat and photolysis. The researchers found six 
different degradation products when photolytic degradation was 
attempted under alkaline conditions. The products were characterized 


























Fig. 3: Five degradation products of HCQ, sixth degradation not characterized [64] 
 
In another study the samples used were HCQ solutions in water from 
a different source; spring, sea, river and ultrapure water and 
photolytic decomposition of HCQ investigated using simulated solar 
radiation (300-800 nm). It was found that humic acids, nitrate and 
iron (III) enhanced the photodegradation of HCQ due to the 
formation of hydroxyl radicals and their attack on the molecule of 
HCQ. Contrary to this, chloride, bromide and sulfate inhibited the 
photodegradation of HCQ [65]. 
Future aspects 
There are a limited number of spectrophotometry methods available 
in the literature. There are many methods available in which 
chromophore is added in molecule by any chemical reaction to 
increase the absorbance in UV region. This is one of the ways to 
increase the sensitivity of method. While going through this 
particular class of analytical method for determination of HCQ, and 
to the best of knowledge of author, no such method has been 
developed and validated. Stability indicating method using 
spectrophotometry analysis is also not found. However, this is also 
well evident that the separation of analytes using simple UV-Vis is 
difficult as compared to chromatographic methods. There are 
different types of chromatographic methods available in the 
literature including HPTLC method. The HPTLC method for the 
determination of HCQ is still needs to be explored. The stability-
indicating HPTLC method is also not available.  
CONCLUSION 
The FDA of United States approved HCQ in 1955 and licensed for a 
treatment option for SLE and inflammatory arthritis before the 
outbreak of new coronavirus. This drug in the current scenario HCQ 
is receiving the attention of our scientists because of its action in 
immune system and antiretroviral effect. India has enormous 
potential and capacity of manufacturing HCQ tablets in large scale. 
There is a surge in demand of HCQ after covid pandemic from almost 
every part of world due to its potential activity against this virus. 
However, more studies are required to establish its activity in 
improving conditions of covid patients. The activity of HCQ against 
covid 19 virus is already discussed in the introductory section. In the 
current scenario, covid is biggest enemy of humanity. The socio-
economical implications due to lockdown is believed to be huge. 
Thus, there is a sudden need for any drug to save the life of covid 
patients and scientists in almost all parts of the world are engaged in 
the development of suitable drug. The review is presented with an 
aim to help scientists or researchers involved in the development of 
the formulation of HCQ. Different spectrophotometry, 
chromatography and electroanalytical methods are presented here 
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